Trainee cardiologists win international competition, a first for Malaysia
(From left) Dr Chen, Dr Yee and Dr Ang receiving a certificate from ACC president Prof Christopher Kramer (second right) and vice-president Prof Roxana Mehran in Singapore.
THREE specialist trainee doctors from Ipoh's Hospital Raja Permaisuri Bainun have made Malaysia proud by winning an esteemed international cardiology competition held in Singapore.
The team, which comprised Dr Chen Tai Meng, Dr Ang Jian-Gang and Dr Yee Shen Yew, won the competition organised by the American College of Cardiology (ACC).
The event was held in conjunction with the ACC Asia 2025 together with the Singapore Cardiac Society Annual Scientific Meeting early last month.
It was also the first time a Malaysian team won the competition since its inception in 2018.
The team will now represent Malaysia to compete in the global ACC's Annual Scientific Session, which will be held in New Orleans in the United States next March.
The International FIT (Fellows-In-Training) Jeopardy competition allows trainee doctors in cardiology to test their clinical knowledge on a range of topics.
These could include prevention, imaging and intervention, selected from hundreds of questions submitted by ACC members.
The Malaysian team defeated the Philippines team and the defending champions from Singapore during the competition.
The Perak team was chosen to represent the country following a national competition held by the National Heart Association of Malaysia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
9 hours ago
- New Straits Times
Malaysia mulls basic medical insurance scheme to tackle rising healthcare costs
KUALA LUMPUR: The Malaysian government is evaluating the introduction of a basic medical insurance scheme aimed at alleviating the financial burden of escalating healthcare costs on the public. Finance Minister II, Datuk Seri Amir Hamzah Azizan, said a joint committee, comprising the Ministry of Finance (MOF), Ministry of Health (MOH), and Bank Negara Malaysia, has been established to study the matter. "Medical inflation is a significant concern for the people. To address this, we have brought together various stakeholders through a joint committee to explore ways to mitigate the impact of rising medical costs," he said at the launch of SME Bank's Budget 2025 financial initiatives. According to Amir Hamzah, one of the proposals under discussion is the introduction of a second account contribution under the Medical and Health Insurance/Takaful (MHIT) product. "Discussions are ongoing to develop a basic insurance scheme for Malaysians. I urge everyone not to speculate on its structure just yet." "Let the relevant parties, including Bank Negara and other stakeholders, deliberate on finding the best possible approach. Once the proposal is finalised, it will be presented in detail," he explained. The MHIT, central to the discussions, was introduced to offer Malaysians affordable access to medical and health insurance or takaful plans. However, with medical costs outpacing general inflation rates, the government aims to enhance the scheme to ensure it continues to meet public needs effectively. On the potential inclusion of SOCSO contributions in the proposal, Amir Hamzah said, "All recommendations are being considered." "However, for now, we are allowing Bank Negara and the involved agencies to discuss the most effective way to establish a basic insurance product for the nation." The outcomes of the discussions and the proposed structure will be announced after thorough deliberations and consultations with relevant stakeholders.
The Star
9 hours ago
- The Star
Trainee cardiologists win international competition, a first for Malaysia
(From left) Dr Chen, Dr Yee and Dr Ang receiving a certificate from ACC president Prof Christopher Kramer (second right) and vice-president Prof Roxana Mehran in Singapore. THREE specialist trainee doctors from Ipoh's Hospital Raja Permaisuri Bainun have made Malaysia proud by winning an esteemed international cardiology competition held in Singapore. The team, which comprised Dr Chen Tai Meng, Dr Ang Jian-Gang and Dr Yee Shen Yew, won the competition organised by the American College of Cardiology (ACC). The event was held in conjunction with the ACC Asia 2025 together with the Singapore Cardiac Society Annual Scientific Meeting early last month. It was also the first time a Malaysian team won the competition since its inception in 2018. The team will now represent Malaysia to compete in the global ACC's Annual Scientific Session, which will be held in New Orleans in the United States next March. The International FIT (Fellows-In-Training) Jeopardy competition allows trainee doctors in cardiology to test their clinical knowledge on a range of topics. These could include prevention, imaging and intervention, selected from hundreds of questions submitted by ACC members. The Malaysian team defeated the Philippines team and the defending champions from Singapore during the competition. The Perak team was chosen to represent the country following a national competition held by the National Heart Association of Malaysia.
The Star
15 hours ago
- The Star
Upbeat outlook for health industry on rising demand
UOBKH Research noted that the hospital segment, in particular, stands out with an earnings growth forecast of 15.1% this year. PETALING JAYA: UOB Kay Hian Research (UOBKH Research) has upgraded the Malaysian healthcare sector to 'overweight,' citing a combination of compelling valuations, strong earnings momentum and 'diminishing policy risk' – with KPJ Healthcare Bhd and Duopharma Biotech Bhd flagged as top picks. In a sectoral update report, the research house said the industry's earnings are 'highly defensive yet attractive, against a backdrop of diminishing policy risk. 'The sector is also supported by structural positives, robust rollouts and resilient domesticated demand,' it said. UOBKH Research noted that the hospital segment, in particular, stands out with an earnings growth forecast of 15.1% this year. This, it said, is against a backdrop of valuations that are currently trading one standard deviation below the sector's five-year mean price-to-earnings ratio. It also sees margin tailwinds as both IHH Healthcare Bhd and KPJ are in the early stages of brownfield expansions. 'These positives far outweigh diminishing policy risk,' it said. Beyond hospitals, UOBKH Research also highlighted non-hospital plays such as Alpha IVF Group Bhd and Duopharma Biotech Bhd for their respective growth drivers. 'Alpha IVF is undertaking exciting regional expansion while Duopharma is expected to see a sharp input cost-led recovery in 2025.' On the policy front, UOBKH Research does not anticipate major disruptions from the planned introduction of a diagnosis-related group (DRG) payment model by year-end, which will initially apply to a 'limited set of simple medical conditions'. 'As a fixed-rate payment model, DRG represents a shift towards value-based care – a direction private hospitals are already moving towards. 'Hence, we do not expect future DRG rollouts to significantly disrupt the operating landscape,' it said. The research firm also downplayed the potential impact of the new drug price transparency rule for private healthcare facilities. 'We believe the drug price display mandate is unlikely to deter patients from purchasing medications directly from their doctors. 'A more impactful measure would be dispensing separation – where doctors prescribe and pharmacists dispense – but this has yet to be formally considered by the Health Ministry.' Similarly, the research house expects 'minimal' impact from the 6% sales and service tax (SST) on private healthcare services for foreigners, which takes effect from July 1, 2025. 'The overall impact is expected to be minimal, as foreign patient revenue accounts for approximately 6% of KPJ's and 1% of IHH's total revenue. 'While foreign patients contribute around 50% of Alpha IVF's revenue, its niche in offering specialised, high-end in vitro fertilisation treatments suggests that demand will likely remain resilient despite the SST expansion.' UOBKH Research named KPJ and Duopharma as its top picks, 'driven by the former's multitude of levers to drive robust earnings growth and the latter's expected cost-led recovery in 2025'. 'In summary, attractive earnings growth, compelling valuations and ongoing positive structural changes support our 'overweight' rating for the healthcare sector. 'In addition, the sector is highly defensive, insulated from external trade that is at risk of a global economic slowdown.'
